Literature DB >> 28303534

Chronic Tobacco-Smoking on Psychopathological Symptoms, Impulsivity and Cognitive Deficits in HIV-Infected Individuals.

Linda Chang1, Ahnate Lim2, Eric Lau2, Daniel Alicata2.   

Abstract

HIV-infected individuals (HIV+) has 2-3 times the rate of tobacco smoking than the general population, and whether smoking may lead to greater psychiatric symptoms or cognitive deficits remains unclear. We evaluated the independent and combined effects of being HIV+ and chronic tobacco-smoking on impulsivity, psychopathological symptoms and cognition. 104 participants [27 seronegative (SN)-non-Smokers, 26 SN-Smokers, 29 HIV+ non-Smokers, 22 HIV+ Smokers] were assessed for psychopathology symptoms (Symptom Checklist-90, SCL-90), depressive symptoms (Center for Epidemiologic Studies-Depression Scale, CES-D), impulsivity (Barratt Impulsiveness Scale, BIS), decision-making (The Iowa Gambling Task, IGT, and Wisconsin Card Sorting Test, WCST), and cognition (seven neurocognitive domains). Both HIV+ and Smoker groups had higher SCL-90 and CES-D scores, with highest scores in HIV+ Smokers. On BIS, both HIV+ and Smokers had higher Total Impulsiveness scores, with higher behavioral impulsivity in Smokers, highest in HIV+ Smokers. Furthermore, across the four groups, HIV+ Smokers lost most money and made fewest advantageous choices on the IGT, and had highest percent errors on WCST. Lastly, HIV+ had lower z-scores on all cognitive domains, with the lowest scores in HIV+ Smokers. These findings suggest that HIV-infection and chronic tobacco smoking may lead to additive deleterious effects on impulsivity, psychopathological (especially depressive) symptoms and cognitive dysfunction. Although greater impulsivity may be premorbid in HIV+ and Smokers, the lack of benefits of nicotine in chronic Smokers on attention and psychopathology, especially those with HIV-infection, may be due to the negative effects of chronic smoking on dopaminergic and cardio-neurovascular systems. Tobacco smoking may contribute to psychopathology and neurocognitive disorders in HIV+ individuals.

Entities:  

Keywords:  Decision making; HIV; Psychopathology; Risk; Tobacco use

Mesh:

Year:  2017        PMID: 28303534      PMCID: PMC5529218          DOI: 10.1007/s11481-017-9728-7

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  67 in total

1.  Smoking history and nicotine effects on cognitive performance.

Authors:  M Ernst; S J Heishman; L Spurgeon; E D London
Journal:  Neuropsychopharmacology       Date:  2001-09       Impact factor: 7.853

2.  Anxiety and HIV infection.

Authors:  A Elliott
Journal:  STEP Perspect       Date:  1998

3.  Delayed nonmatch-to-sample performance in HIV-seropositive and HIV-seronegative polydrug abusers.

Authors:  Eileen M Martin; David L Pitrak; Niles Rains; Silvana Grbesic; Kenneth Pursell; Gerald Nunnally; Antoine Bechara
Journal:  Neuropsychology       Date:  2003-04       Impact factor: 3.295

4.  Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Authors:  Paula L Vieira-Brock; Lisa M McFadden; Shannon M Nielsen; Jonathan D Ellis; Elliot T Walters; Kristen A Stout; J Michael McIntosh; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2015-09-21       Impact factor: 4.030

5.  Depressive and anxiety disorders in women with HIV infection.

Authors:  Mary F Morrison; John M Petitto; Thomas Ten Have; David R Gettes; Margaret S Chiappini; Anita L Weber; Priscilla Brinker-Spence; Russell M Bauer; Steven D Douglas; Dwight L Evans
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

6.  Neural correlates of attention and working memory deficits in HIV patients.

Authors:  L Chang; O Speck; E N Miller; J Braun; J Jovicich; C Koch; L Itti; T Ernst
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

7.  Adaptation of the attention network in human immunodeficiency virus brain injury.

Authors:  Linda Chang; Dardo Tomasi; Renat Yakupov; Carl Lozar; Sheeba Arnold; Elisabeth Caparelli; Thomas Ernst
Journal:  Ann Neurol       Date:  2004-08       Impact factor: 10.422

Review 8.  Personality, psychopathology, and nicotine response as mediators of the genetics of smoking.

Authors:  D G Gilbert; B O Gilbert
Journal:  Behav Genet       Date:  1995-03       Impact factor: 2.805

9.  Cognitive impairment in HIV and HCV co-infected patients: a systematic review and meta-analysis.

Authors:  Renata Fialho; Marco Pereira; Mihaela Bucur; Martin Fisher; Richard Whale; Jennifer Rusted
Journal:  AIDS Care       Date:  2015-11-05

10.  HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.

Authors:  Robert K Heaton; Donald R Franklin; Ronald J Ellis; J Allen McCutchan; Scott L Letendre; Shannon Leblanc; Stephanie H Corkran; Nichole A Duarte; David B Clifford; Steven P Woods; Ann C Collier; Christina M Marra; Susan Morgello; Monica Rivera Mindt; Michael J Taylor; Thomas D Marcotte; J Hampton Atkinson; Tanya Wolfson; Benjamin B Gelman; Justin C McArthur; David M Simpson; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Terry L Jernigan; Joseph Wong; Igor Grant
Journal:  J Neurovirol       Date:  2010-12-21       Impact factor: 2.643

View more
  14 in total

Review 1.  Modulatory Effects of Nicotine on neuroHIV/neuroAIDS.

Authors:  Haijun Han; Zhongli Yang; Sulie L Chang; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-13       Impact factor: 4.147

2.  Tobacco use and HIV symptom severity in Chinese people living with HIV.

Authors:  Wei-Ti Chen; Chengshi Shiu; Joyce P Yang; Myo Mie Mie Tun; Lin Zhang; Kerong Wang; Li-Chen Chen; Myo Nyein Aung; Hongzhou Lu; Hongxin Zhao
Journal:  AIDS Care       Date:  2019-05-22

3.  Cigarette smoking duration mediates the association between future thinking and norepinephrine level.

Authors:  Jenny E Ozga; Nicholas J Felicione; Melissa D Blank; Nicholas A Turiano
Journal:  Addict Behav       Date:  2018-06-18       Impact factor: 3.913

4.  Contributions of chronic tobacco smoking to HIV-associated brain atrophy and cognitive deficits.

Authors:  Hua-Jun Liang; Thomas Ernst; Eric Cunningham; Linda Chang
Journal:  AIDS       Date:  2022-03-15       Impact factor: 4.177

5.  A qualitative study of the feasibility and acceptability of a smoking cessation program for people living with HIV and emotional dysregulation.

Authors:  A K Labbe; J G Wilner; J N Coleman; S M Marquez; J D Kosiba; M J Zvolensky; J A J Smits; P J Norton; D Rosenfield; C O'Cleirigh
Journal:  AIDS Care       Date:  2018-10-23

Review 6.  Bidirectional Associations among Nicotine and Tobacco Smoke, NeuroHIV, and Antiretroviral Therapy.

Authors:  Shivesh Ghura; Robert Gross; Kelly Jordan-Sciutto; Jacob Dubroff; Robert Schnoll; Ronald G Collman; Rebecca L Ashare
Journal:  J Neuroimmune Pharmacol       Date:  2019-12-13       Impact factor: 4.147

7.  Cigarette smoke and nicotine effects on brain proinflammatory responses and behavioral and motor function in HIV-1 transgenic rats.

Authors:  Walter Royal; Adem Can; Todd D Gould; Ming Guo; Jared Huse; Myles Jackson; Harry Davis; Joseph Bryant
Journal:  J Neurovirol       Date:  2018-04-11       Impact factor: 2.643

8.  Independent and Combined Effects of Chronic HIV-Infection and Tobacco Smoking on Brain Microstructure.

Authors:  Huajun Liang; Linda Chang; Rong Chen; Kenichi Oishi; Thomas Ernst
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-17       Impact factor: 4.147

9.  The effect of varenicline on mood and cognition in smokers with HIV.

Authors:  Morgan Thompson; Robert Schnoll; Katrina Serrano; Frank Leone; Robert Gross; Ronald G Collman; Rebecca L Ashare
Journal:  Psychopharmacology (Berl)       Date:  2020-01-14       Impact factor: 4.530

10.  No differences in delay discounting between smokers with and without HIV.

Authors:  Cory Czuczman; Morgan Thompson; E Paul Wileyto; Robert Schnoll; David Metzger; Frank Leone; Karam Mounzer; Robert Gross; Rebecca L Ashare
Journal:  Psychopharmacology (Berl)       Date:  2020-11-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.